Guidance, NICE advice and quality standards In development
Showing 11 to 15 of 15
Title | Type | Expected publication date |
---|---|---|
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935] | Technology appraisal guidance | TBC |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |